Table 5.

Univariate and multivariate cox analyses for disease-free survival in primary tumors.

Parameter	Category	Event	Total	Univariate HR (95% CI)	p-value	Multivariate HR (95% CI)	p-value
Diagnosis age (years)		27	46	1.02 (1.00, 1.05)	0.060
Sex	Male	13	20	Ref
	Female	14	26	0.87 (0.41, 1.86)	0.725
Histotype	UPS/MFH	23	42	Ref		Ref
	Radiation associated UPS	4	4	3.59 (1.17, 11.0)	0.025	4.62 (1.43, 14.9)	0.011
Site	Lower extremities	13	25	Ref
	Others	14	21	1.30 (0.61, 2.76)	0.500
Depth	superficial	12	18	Ref
	deep	15	28	0.74 (0.35, 1.59)	0.445
Size	< 5cm	7	18	Ref		Ref
	5 - 10cm	12	19	2.63 (1.02, 6.77)	0.045	2.41 (0.93, 6.27)	0.070
	> 10cm	8	9	5.91 (2.10, 16.6)	<0.001	6.86 (2.41, 19.5)	<0.001
Preoperative chemotherapy	No	22	37	Ref
	Yes	5	9	1.00 (0.38, 2.65)	0.999
Preoperative RT	No	20	32	Ref
	Yes	7	14	0.72 (0.30, 1.71)	0.459
LA	No	20	33	Ref
	Yes	4	10	0.46 (0.16, 1.36)	0.161
Biomarkers*
CD3	Low	18	23	Ref		Ref
	High	9	23	0.29 (0.13, 0.67)	0.003	0.34 (0.14, 0.83)	0.018
CD8	Low	18	23	Ref		Ref
	High	9	23	0.30 (0.13, 0.69)	0.005	0.34 (0.14, 0.81)	0.014
CD20	Low	12	22	Ref
	High	14	22	1.40 (0.64, 3.03)	0.398
ICOS	Low	15	21	Ref
	High	10	22	0.50 (0.22, 1.14)	0.100
OX40	Low	17	28	Ref
	High	9	16	1.04 (0.46, 2.35)	0.917
LAG3	Low	26	43	Ref
	High	0	1	NA	NA
IDO1	Low	24	41	Ref
	High	2	4	0.64 (0.15, 2.71)	0.545
PD1	Low	16	23	Ref
	High	11	23	0.59 (0.27, 1.28)	0.185
PDL1	Low	23	36	Ref
	High	4	9	0.61 (0.21, 1.78)	0.362
CD73	Low	15	22	Ref
	High	11	22	0.78 (0.36, 1.71)	0.539
CD39	Low	15	23	Ref
	High	12	23	0.61 (0.28, 1.31)	0.201
CD163	Low	17	23	Ref
	High	10	23	0.46 (0.21, 1.02)	0.055

*Each biomarker was categorized as high or low based on the median and if significantly associated with survival in univariate analysis was subsequently included in a backward model adjusted for histotype and tumor size.

95%CI, 95% confidence interval; HR, hazard ratio; LA, lymphoid aggregates; MFH, malignant fibrous histiocytoma; NA, Not Applicable; RT, radiation therapy; UPS, undifferentiated pleomorphic sarcoma.

Bold values indicate significant p-value.